Top Page
Cryosite Limited
(Sydney:CTE)
Cryosite Limited (CTE) vs. iShares MSCI Australia ETF (EWA)
Cryosite Limited Business Overview & Revenue Model
Cryosite Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.85M | 14.12M | 12.61M | 11.94M | 11.76M | 10.02M |
| Gross Profit | 7.89M | 8.89M | 7.99M | 6.48M | 6.27M | 5.31M |
| EBITDA | 3.21M | 3.41M | 3.04M | 2.34M | 2.45M | 1.65M |
| Net Income | 1.83M | 1.88M | 1.84M | 1.41M | 1.36M | 652.57K |
Balance Sheet | ||||||
| Total Assets | 19.09M | 19.46M | 19.71M | 22.65M | 21.50M | 21.99M |
| Cash, Cash Equivalents and Short-Term Investments | 4.49M | 5.06M | 4.70M | 5.73M | 5.34M | 3.88M |
| Total Debt | 2.36M | 2.27M | 2.44M | 2.61M | 849.76K | 1.07M |
| Total Liabilities | 17.77M | 17.07M | 18.26M | 19.86M | 19.64M | 21.17M |
| Stockholders Equity | 1.31M | 2.39M | 1.45M | 2.78M | 1.86M | 819.23K |
Cash Flow | ||||||
| Free Cash Flow | 2.20M | 1.48M | 2.44M | 1.19M | 1.63M | 80.07K |
| Operating Cash Flow | 2.76M | 2.06M | 2.90M | 1.49M | 2.49M | 476.96K |
| Investing Cash Flow | -561.00K | -420.00K | 727.00K | -1.33M | -863.19K | -396.89K |
| Financing Cash Flow | -3.72M | -1.29M | -3.50M | -768.00K | -148.99K | -260.78K |
Cryosite Limited Technical Analysis
Cryosite Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$49.54M | 26.30 | 98.18% | ― | 11.93% | 2.39% | |
52 Neutral | AU$28.91M | ― | -97.79% | ― | ― | 23.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$29.65M | ― | -501.54% | ― | ― | 56.42% | |
47 Neutral | AU$168.96M | ― | -111.23% | ― | 12.96% | 40.81% | |
42 Neutral | AU$49.93M | ― | -40.54% | ― | 29.60% | 33.00% | |
38 Underperform | AU$48.57M | ― | -37.78% | ― | 2.33% | 12.50% |
Cryosite Limited Corporate Events
Cryosite Limited held its Annual General Meeting, where all resolutions, including the adoption of the remuneration report, the company’s option plan, and the re-election of a director, were carried with significant support. This outcome reflects strong shareholder confidence in the company’s strategic direction and governance, potentially enhancing its market position and stakeholder trust.
The most recent analyst rating on (AU:CTE) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cryosite Limited stock, see the AU:CTE Stock Forecast page.
Cryosite Limited reported strong financial performance in Q1 FY26, with significant revenue and profit growth driven by increased demand across its key segments. The company is expanding its operations with a new warehouse facility to enhance capacity and service offerings, while continuing to grow its client base and diversify revenue streams. The company’s leadership in temperature-controlled storage and logistics is recognized, positioning it well to meet rising demand in the industry.
The most recent analyst rating on (AU:CTE) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cryosite Limited stock, see the AU:CTE Stock Forecast page.
Cryosite Limited has announced the acquisition of a strategic warehouse facility in Auburn, NSW, marking a significant step in its growth strategy. This acquisition will more than double the company’s storage capacity, addressing current capacity constraints and enabling future revenue growth. The facility’s strategic location and operational fit will enhance Cryosite’s logistics capabilities, while the financial terms of the acquisition are favorable compared to leasing options. The expansion will also support new revenue streams and business continuity, with plans to relocate certain operations to the new site and apply for necessary regulatory approvals.
The most recent analyst rating on (AU:CTE) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cryosite Limited stock, see the AU:CTE Stock Forecast page.
Cryosite Limited has announced its Annual General Meeting of Shareholders, scheduled for October 16, 2025, in Melbourne. The meeting notice is available electronically, and shareholders are encouraged to contact the share registry for further communications. This announcement highlights Cryosite’s commitment to maintaining transparency and engagement with its stakeholders, potentially impacting its operational strategies and industry positioning.
The most recent analyst rating on (AU:CTE) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cryosite Limited stock, see the AU:CTE Stock Forecast page.
Cryosite Limited reported a strong financial performance for FY25, marked by record revenues and operational achievements. The company launched a new Ultra-Frozen and Cryogenic revenue segment, positioning itself strategically in the healthcare industry. With a 12% increase in revenue to $14.1 million and a 19% rise in EBITDA to $3.4 million, Cryosite is expanding its capacity to meet growing client demand without requiring additional capital. The company also achieved significant growth in its Ultra-Frozen and Cryogenic segment, with a 58% increase in revenue, and is actively pursuing expansion opportunities to capitalize on the projected growth in biotechnology and advanced therapy medicinal products.
The most recent analyst rating on (AU:CTE) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Cryosite Limited stock, see the AU:CTE Stock Forecast page.
Cryosite Limited has released a corporate presentation that provides an overview of its current activities and financial information. The presentation is not an offer for securities but serves as a general informational document. It emphasizes that the information is based on reliable sources but has not been independently verified. The company advises caution regarding forward-looking statements, which are subject to change and involve risks and uncertainties. Stakeholders are encouraged to conduct their own assessments before making investment decisions.
The most recent analyst rating on (AU:CTE) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Cryosite Limited stock, see the AU:CTE Stock Forecast page.
Cryosite Limited has released its corporate governance statement for the financial year ending June 30, 2025. The statement, which is available on the company’s website, details the extent to which Cryosite has adhered to the ASX Corporate Governance Council’s recommendations. The company has disclosed its governance practices, including board responsibilities and the process for appointing directors, which are aimed at ensuring transparency and accountability. This announcement underscores Cryosite’s commitment to maintaining robust governance standards, potentially enhancing its reputation and trust among stakeholders.
The most recent analyst rating on (AU:CTE) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Cryosite Limited stock, see the AU:CTE Stock Forecast page.
Cryosite Limited reported a 12% increase in revenue to $14.1 million for the fiscal year ending June 30, 2025, with a 21% rise in profit before tax. The company experienced stronger trading conditions in the latter half of the year, contributing to a 19% increase in EBITDA. Despite these gains, the company decided not to declare a dividend for FY25, opting instead to focus on expansion plans, including securing a second facility to support future growth. This strategic decision is backed by a strong balance sheet and robust cash flows, allowing Cryosite to expand without raising additional capital.
The most recent analyst rating on (AU:CTE) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Cryosite Limited stock, see the AU:CTE Stock Forecast page.
Cryosite Limited has announced that its Annual General Meeting will take place on October 16, 2025, in Melbourne. The company has set August 28, 2025, as the closing date for director nominations. This announcement is part of Cryosite’s ongoing commitment to maintaining transparent communication with its stakeholders, ensuring they are informed about key governance events.